Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9ULX7

UPID:
CAH14_HUMAN

ALTERNATIVE NAMES:
Carbonate dehydratase XIV; Carbonic anhydrase XIV

ALTERNATIVE UPACC:
Q9ULX7; Q5TB24; Q8NCF4

BACKGROUND:
The enzyme Carbonic anhydrase 14, with aliases such as Carbonate dehydratase XIV and Carbonic anhydrase XIV, is integral to the reversible hydration of carbon dioxide. It is essential for regulating the acid-base balance across various biological contexts, converting carbon dioxide and water into bicarbonate and protons efficiently.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionality of Carbonic anhydrase 14 unveils opportunities for innovative therapeutic interventions. Given its central role in acid-base homeostasis, targeting this enzyme could lead to novel treatments for conditions where this balance is compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.